{"id":8990,"date":"2025-10-21T09:38:52","date_gmt":"2025-10-21T06:38:52","guid":{"rendered":"https:\/\/jordan-cardiac.org\/?p=8990"},"modified":"2025-10-21T09:38:52","modified_gmt":"2025-10-21T06:38:52","slug":"fda-updates-fenofibrate-labeling-no-proven-cardiovascular-benefit","status":"publish","type":"post","link":"https:\/\/jordan-cardiac.org\/en\/fda-updates-fenofibrate-labeling-no-proven-cardiovascular-benefit\/","title":{"rendered":"FDA Updates Fenofibrate Labeling \u2014 No Proven Cardiovascular Benefit"},"content":{"rendered":"<div>FDA Updates Fenofibrate Labeling \u2014 No Proven Cardiovascular Benefit<\/div>\n<div><\/div>\n<div>Source: Medical News highlighting; Official FDA Label Update: TRICOR (Fenofibrate) tablets \u2013 Prescribing Information, 2025 (accessdata.fda.gov).<\/div>\n<div><\/div>\n<div>1. Background<\/div>\n<div><span> \u2022 Fenofibrates are lipid-modifying agents that lower triglycerides (TG) and modestly raise HDL cholesterol, commonly used in patients with mixed dyslipidemia.<\/span><\/div>\n<div><span> \u2022 Historically, they were believed to provide cardiovascular protection, especially when combined with statins. However, multiple outcome trials have consistently failed to show this benefit.<\/span><\/div>\n<div><\/div>\n<div>2. FDA Decision<\/div>\n<div><span> \u2022 In\u00a0 2025, the U.S. Food and Drug Administration (FDA) finalized a labeling update confirming that fenofibrate therapy provides no proven cardiovascular benefit.<\/span><\/div>\n<div><span> \u2022 The decision was based on large-scale studies such as FIELD, ACCORD-Lipid, and PROMINENT, all showing neutral cardiovascular outcomes despite lipid improvements.<\/span><\/div>\n<div><span> \u2022 The new labeling also highlights a potential increased risk of venous thromboembolism, as observed in the PROMINENT trial (2022).<\/span><\/div>\n<div><\/div>\n<div>3. How the FDA Decision Evolved<\/div>\n<div><span> \u2022 The process began when HealthyWomen, a U.S. nonprofit organization advocating for women\u2019s health, submitted a citizen petition (Docket No. FDA-2024-P-1988) in 2024, requesting clearer labeling to prevent misleading cardiovascular claims.<\/span><\/div>\n<div><span> \u2022 The FDA conducted a scientific review of all clinical data, including trial outcomes and post-marketing surveillance.<\/span><\/div>\n<div><span> \u2022 After verification, the FDA issued its final decision in mid-2025, amending official product labels (e.g., TRICOR) to align with real-world evidence.<\/span><\/div>\n<div><span> \u2022 This process demonstrates how long-term scientific review and patient advocacy can reshape clinical practice\u2014ensuring that drug labeling reflects evidence-based medicine and promotes rational prescribing.<\/span><\/div>\n<div><\/div>\n<div>4. Clinical Implications<\/div>\n<div><span> \u2022 Fibrates should not be used for cardiovascular risk reduction.<\/span><\/div>\n<div><span> \u2022 Their primary role is the management of severe hypertriglyceridemia (\u2265500 mg\/dL) to prevent acute pancreatitis, not to lower ASCVD risk.<\/span><\/div>\n<div><span> \u2022 Statins remain the cornerstone of lipid therapy for atherosclerotic prevention.<\/span><\/div>\n<div><\/div>\n<div>When Triglycerides Remain Elevated After Maximal Statin Therapy:<\/div>\n<div><span> \u2022 Reassess secondary causes (e.g., diabetes, hypothyroidism, renal disease, alcohol, or medications).<\/span><\/div>\n<div><span> \u2022 Optimize lifestyle: adopt a Mediterranean or low-carb diet, exercise \u2265150 min\/week, achieve \u22655\u201310% weight loss, and avoid alcohol if TG &gt; 500 mg\/dL.<\/span><\/div>\n<div><span> \u2022 Confirm maximal tolerated statin dose and LDL-C control before adding any agent.<\/span><\/div>\n<div><span> \u2022 Add-on options:<\/span><\/div>\n<div><span> \u2022 If TG = 150\u2013499 mg\/dL \u2192 add icosapent ethyl (EPA 4 g\/day) for cardiovascular event reduction (REDUCE-IT, NEJM 2019).<\/span><\/div>\n<div><span> \u2022 If TG \u2265 500 mg\/dL \u2192 fenofibrate may be added only to reduce the risk of pancreatitis, not for CV prevention. Ensure stable renal function and close monitoring if used alongside statins.<\/span><\/div>\n<div><span> \u2022 Niacin is no longer recommended due to lack of benefit and increased adverse effects.<\/span><\/div>\n<div><\/div>\n<div>5. Key Takeaway<\/div>\n<div><\/div>\n<div>This FDA update reflects a broader movement toward precision and accountability in cardiovascular pharmacotherapy:<\/div>\n<div><span> \u2022 Fenofibrates retain a role for triglyceride control in pancreatitis prevention,<\/span><\/div>\n<div><span> \u2022 but should not be used for cardiovascular event reduction, even after maximal statin therapy.<\/span><\/div>\n<div><span> \u2022 The decision also highlights how evidence-based regulatory action\u2014initiated by patient advocacy and sustained by rigorous FDA review\u2014can correct misconceptions and drive better clinical practice worldwide.<\/span><\/div>\n<div><\/div>\n<div><\/div>\n<div><a href=\"https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/021656s032lbl.pdf\">https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/021656s032lbl.pdf<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>FDA Updates Fenofibrate Labeling \u2014 No Proven Cardiovascular Benefit Source: Medical News highlighting; Official FDA Label Update: TRICOR (Fenofibrate) tablets \u2013 Prescribing Information, 2025 (accessdata.fda.gov). 1. Background \u2022 Fenofibrates are lipid-modifying agents that lower triglycerides (TG) and modestly raise HDL cholesterol, commonly used in patients with mixed dyslipidemia. \u2022 Historically, they were believed to provide [&hellip;]<\/p>\n","protected":false},"author":145,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-8990","post","type-post","status-publish","format-standard","hentry","category-uncategorized"],"_links":{"self":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/8990","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/users\/145"}],"replies":[{"embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/comments?post=8990"}],"version-history":[{"count":1,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/8990\/revisions"}],"predecessor-version":[{"id":8991,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/8990\/revisions\/8991"}],"wp:attachment":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/media?parent=8990"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/categories?post=8990"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/tags?post=8990"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}